CervoMed’s (CRVO) “Buy” Rating Reiterated at HC Wainwright

CervoMed (NASDAQ:CRVO)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. HC Wainwright also issued estimates for CervoMed’s Q4 2026 earnings at ($0.59) EPS, FY2026 earnings at ($2.70) EPS, Q1 2027 earnings at ($0.51) EPS, Q2 2027 earnings at ($0.46) EPS, Q3 2027 earnings at ($0.50) EPS, Q4 2027 earnings at ($0.53) EPS and FY2027 earnings at ($1.99) EPS.

A number of other equities research analysts have also recently issued reports on the company. Chardan Capital upped their price objective on CervoMed from $15.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, March 18th. Roth Capital set a $9.00 target price on shares of CervoMed in a report on Monday, May 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CervoMed in a research report on Monday, April 20th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $31.00 price target on shares of CervoMed in a research note on Wednesday, April 22nd. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $22.60.

CervoMed Price Performance

CervoMed stock opened at $3.08 on Wednesday. The company has a market cap of $41.67 million, a price-to-earnings ratio of -0.94 and a beta of -0.68. The firm has a 50-day moving average of $3.34 and a 200-day moving average of $4.48. CervoMed has a one year low of $2.13 and a one year high of $13.13.

CervoMed (NASDAQ:CRVO) last released its earnings results on Friday, May 15th. The company reported ($0.86) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.04. CervoMed had a negative return on equity of 136.08% and a negative net margin of 672.80%. As a group, sell-side analysts expect that CervoMed will post -2.84 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Joshua S. Boger acquired 955,414 shares of the firm’s stock in a transaction on Thursday, June 11th. The shares were purchased at an average cost of $3.14 per share, for a total transaction of $2,999,999.96. Following the completion of the acquisition, the director directly owned 1,795,865 shares in the company, valued at approximately $5,639,016.10. This trade represents a 113.68% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. 35.80% of the stock is currently owned by company insiders.

Institutional Trading of CervoMed

A number of hedge funds have recently modified their holdings of the stock. Rhumbline Advisers grew its position in shares of CervoMed by 35.5% in the first quarter. Rhumbline Advisers now owns 5,830 shares of the company’s stock valued at $53,000 after purchasing an additional 1,526 shares during the last quarter. State Street Corp lifted its holdings in CervoMed by 11.4% during the 4th quarter. State Street Corp now owns 20,527 shares of the company’s stock worth $162,000 after purchasing an additional 2,100 shares during the last quarter. Vanguard Group Inc. lifted its holdings in CervoMed by 1.0% during the 3rd quarter. Vanguard Group Inc. now owns 343,463 shares of the company’s stock worth $2,779,000 after purchasing an additional 3,445 shares during the last quarter. Citizens Financial Group Inc. RI boosted its stake in CervoMed by 23.0% in the 4th quarter. Citizens Financial Group Inc. RI now owns 37,477 shares of the company’s stock valued at $296,000 after purchasing an additional 7,000 shares during the period. Finally, XTX Topco Ltd bought a new stake in CervoMed in the 4th quarter valued at $81,000. Institutional investors and hedge funds own 25.15% of the company’s stock.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.